Navigating Biologics and Biosimilars in Psoriasis and Hidradenitis Suppurativa

The session discusses the increasing array of biologics and biosimilars available for treating psoriasis and hidradenitis suppurativa (HS). It emphasizes the complexity of biologics—large, intricate molecules produced by living systems—and clarifies misconceptions patients may have about their administration and safety compared to traditional medications. The introduction of biosimilars as cost-effective alternatives to biologics, particularly adalimumab, is highlighted, noting that these products undergo reverse engineering rather than being direct generics. A comprehensive exploration of cytokines involved in HS showcases its complexity, contrasting it with the relatively straightforward pathways in psoriasis. The talk examines established treatments like adalimumab and newer options, including psychokinimab and IL-17 inhibitors, noting their varying effects and the challenges of clinical trial outcomes in HS, which may not align with those in psoriasis. Additionally, potential future treatments, including novel monoclonal antibodies and therapies targeting interleukin pathways, are discussed. The speaker expresses optimism regarding ongoing research and expects advancements that will improve treatment efficacy in HS and potentially lead to better patient outcomes.